Achaogen, Inc.
AKAO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AKAO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2018.
Tracking 3 pipeline candidates for Achaogen, Inc..
Run Achaogen, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Achaogen, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
3.8 months
Net income -$48M
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is Achaogen, Inc.'s lead drug candidate?
Achaogen, Inc.'s most advanced tracked candidate is c-scape (Phase 1) for serious bacterial infections due to expanded spectrum beta-lactamases (ESBL) producing Enterobacteriaceae.
What therapeutic areas does Achaogen, Inc. focus on?
Achaogen, Inc. develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.